Stock listing
Tradegate:CN2 Catalyst Pharmaceuticals, Inc. Aktie
German listing (Tradegate) of Catalyst Pharmaceuticals, Inc. · home listing NASDAQ:CPRX
Follow Catalyst Pharmaceuticals, Inc. into a list and get an email when it puts out news.

- Ticker
- Tradegate:CN2
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Jun 30, 2026
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Latest earnings call · Feb 26, 2026
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2025 Earnings Call
Replay and transcript
Latest deck · Feb 26, 2026
Q4 2025 Earnings Presentation
Earnings · 21 slides
Latest news
Catalyst Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 13 in the last 12 months · 180 in all · newest Jun 30, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest Feb 26, 2026
- Decks
- 6 decks · latest Feb 26, 2026
Where Catalyst Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CPRX · Home listing | NASDAQ | United States | USD |
| gettex:CN2 | gettex | Germany | EUR |
| LS Exchange:A0LCUL | LS Exchange | Germany | EUR |
| BOATS:CPRX | BOATS | United States | USD |
| Tradegate:CN2 · This page | Tradegate | Germany | EUR |
| Frankfurt:CN2 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A0LCUL | Lang & Schwarz | Germany | EUR |
| BX Swiss:CN2 | BX Swiss | Switzerland | CHF |
| Stuttgart:CN2 | Stuttgart | Germany | EUR |
| Dusseldorf:CN2 | Dusseldorf | Germany | EUR |
| Hamburg:CN2 | Hamburg | Germany | EUR |
| Munich:CN2 | Munich | Germany | EUR |
Valuation
Statements: 4 quarters to Mar 31, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- 82.3%
- Operating margin
- 44.8%
- Net margin
- 37.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 31.67 USD · Analysts' mean
- EPS, year to Dec 2026
- 3.17 · 1 analyst
- Revenue, year to Dec 2026
- 636.2M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mary Coleman | Investor Relations |
| Chantal Dresner | VP of Marketing |
| Roberto Scrivo | Chief External Affairs Communication & Sustainability Officer |
| William T. Andrews | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Daniel Curran | Director |
| Internal Communication | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2023 Earnings Call | Thu, Feb 29, 2024 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 8:30 AM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2023 Earnings Call | Thu, Aug 10, 2023 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2023 Earnings Call | Thu, May 11, 2023 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2022 Earnings Call | Thu, Mar 16, 2023 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2022 Earnings Call | Wed, Aug 10, 2022 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2022 Earnings Call | Wed, May 11, 2022 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2021 Earnings Call | Thu, Mar 17, 2022 · 8:30 AM ET | Replay |
| Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results |
|---|---|
| Q1 2026 | May 11, 2026 · After close |
| Q4 2025 | Mar 18, 2026 |
| Q3 2025 | Nov 5, 2025 · After close |
| Q2 2025 | Aug 6, 2025 · After close |
| Q1 2025 | May 6, 2025 · Before open |
| Q4 2024 | Feb 26, 2025 · After close |
| Q3 2024 | Nov 6, 2024 · After close |
| Q2 2024 | Aug 7, 2024 · After close |
| Q1 2024 | May 8, 2024 · After close |
| Q4 2023 | Feb 28, 2024 · After close |
All 20 quarters
| Quarter | Results |
|---|---|
| Q3 2023 | Nov 8, 2023 · After close |
| Q2 2023 | Aug 9, 2023 · After close |
| Q1 2023 | May 10, 2023 · After close |
| Q4 2022 | Mar 15, 2023 · After close |
| Q3 2022 | Nov 9, 2022 · After close |
| Q2 2022 | Aug 9, 2022 · After close |
| Q1 2022 | May 10, 2022 · After close |
| Q4 2021 | Mar 16, 2022 · After close |
| Q3 2021 | Nov 9, 2021 · After close |
| Q2 2021 | Aug 9, 2021 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2025 Earnings Presentation | Earnings | 21 slides | Feb 26, 2026 |
| Investor Presentation (January 2026) | Investor deck | 21 slides | Jan 12, 2026 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 20 slides | Jan 13, 2025 |
| Investor Presentation (January 2024) | Investor deck | 26 slides | Jan 8, 2024 |
| Investor Presentation (September 2023) | Investor deck | 25 slides | Sep 26, 2023 |
| Catalyst Pharmaceutical Partners — BIO CEO Investor Conference 2013 | Conference | 27 slides | Feb 14, 2013 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 589.0M | 491.7M | 398.2M | 214.2M | 140.8M | 119.1M | 102.3M | 500.0K | 0 | 0 |
| Cost of revenue | 87.3M | 68.8M | 52.0M | 34.4M | 21.9M | 17.0M | 14.8M | 19.9M | 45.7K | 43.4K |
| Gross profit | 501.7M | 422.9M | 346.2M | 179.8M | 118.9M | 102.0M | 87.5M | 500.0K | -45.7K | -43.4K |
| Research and development | 12.7M | 12.6M | 93.2M | 19.8M | 16.9M | 16.5M | 18.8M | 19.9M | 11.4M | 11.4M |
| Selling, general and administrative | 71.5M | 167.7M | 47.0M | 28.7M | 23.5M | 20.7M | 36.9M | 15.9M | 7.30M | 7.91M |
| Operating income | 257.8M | 195.1M | 86.8M | 101.8M | 52.4M | 41.3M | 31.8M | -35.3M | -18.7M | -19.3M |
| Depreciation and amortization | 37.9M | 37.8M | 32.9M | 1.24M | 192.0K | 885.3K | 297.7K | 38.0K | 45.7K | 43.4K |
| EBITDA | 295.7M | 232.9M | 119.7M | 103.1M | 52.6M | 42.2M | 32.1M | -35.3M | -18.6M | -19.2M |
| Interest expense | 4.12M | 474.0K | 1.47M | 1.88M | 1.29M | 454.2K | 321.6K | |||
| Income before tax | 283.5M | 216.3M | 94.5M | 104.7M | 52.7M | 41.9M | 33.4M | -34.0M | -18.4M | -18.1M |
| Income tax | 69.2M | 52.4M | 23.1M | 21.6M | 13.2M | -33.1M | 1.53M | 2.58M | 141.2K | -929.5K |
| Net income | 214.3M | 163.9M | 71.4M | 83.1M | 39.5M | 75.0M | 31.9M | -34.0M | -18.4M | -18.1M |
| Earnings per share, basic | 1.68 | 1.31 | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | -0.33 | -0.21 | -0.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 709.2M | 517.6M | 137.6M | 298.4M | 171.4M | 130.2M | 89.5M | 16.6M | 57.5M | 13.9M |
| Short-term investments | 0 | 19.8M | 10.0M | 5.01M | 36.9M | 26.5M | 26.5M | |||
| Receivables | 128.3M | 65.5M | 53.5M | 10.8M | 6.72M | 5.99M | 10.5M | |||
| Inventory | 37.2M | 19.5M | 15.6M | 6.80M | 7.87M | 4.65M | 1.96M | 56.0K | 0 | 0 |
| Current assets | 894.0M | 623.6M | 219.3M | 320.8M | 210.1M | 159.2M | 111.4M | 55.2M | 85.2M | 41.5M |
| Property, plant and equipment | 847.0K | 3.98M | 129.8K | 210.5K | 245.4K | 191.4K | 244.2K | |||
| Goodwill | 0 | 0 | ||||||||
| Total assets | 1.11B | 851.4M | 470.1M | 375.6M | 237.8M | 192.4M | 112.4M | 60.4M | 85.4M | 41.7M |
| Accounts payable | 11.2M | 16.6M | 14.8M | 3.98M | 2.77M | 4.26M | 4.12M | 2.34M | 1.95M | 933.2K |
| Current liabilities | 147.2M | 120.7M | 76.1M | 57.6M | 27.1M | 22.8M | 24.1M | 9.51M | 4.27M | 2.09M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 2.79M | 3.19M | 3.56M | 3.89M | 4.20M | 29.0K | 948.0K | |||
| Total liabilities | 152.5M | 123.8M | 82.2M | 75.2M | 31.0M | 22.8M | 24.7M | 9.67M | 4.42M | 2.40M |
| Shareholders' equity | 954.3M | 727.6M | 387.9M | 300.4M | 206.8M | 169.6M | 87.6M | 50.8M | 81.0M | 39.3M |
| Shares outstanding | 127.3M | 124.9M | 113.8M | 111.4M | 107.8M | 106.2M | 106.0M | 102.6M | 85.8M | 82.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 208.7M | 239.8M | 143.6M | 116.0M | 60.4M | 45.0M | 34.6M | -25.7M | -13.7M | -18.0M |
| Capital spending | -58.0K | -556.0K | -81.7M | -29.0K | -1.02M | -11.4K | -19.4K | -92.0K | -92.0K | -96.1K |
| Free cash flow | 208.6M | 239.3M | 61.9M | 116.0M | 59.4M | 45.0M | 34.6M | -25.8M | -13.7M | -18.1M |
| Cash from investing | -58.0K | -556.0K | -293.5M | 9.21M | -11.0M | -5.01M | 37.2M | -15.5M | -3.96K | 3.55M |
| Cash from financing | -17.0M | 140.7M | -10.9M | 1.69M | -8.14M | 701.9K | 1.12M | 293.1K | 57.4M | 69.0K |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | -25.3M | -296.0K | -982.0K | -6.91M | -12.1M | -56.0K | 1.12M | -4.45K | 57.4M | -11.3K |
| Change in cash | 191.6M | 379.9M | -160.8M | 127.0M | 41.2M | 40.7M | 73.0M | -40.9M | 43.6M | -14.3M |
Cap table
Built by 6ix from Catalyst Pharmaceuticals, Inc.’s releases
- Common shares
- 122,417,458
- Fully diluted
- 122,417,458
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 122,417,458 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 122,417,458 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William T. Andrews Other companies: Flexion Therapeutics Inc (Chief Medical Officer · Jul 1, 2021 – Nov 19, 2021 · Past); Akcea Therapeutics Inc (Chief Medical Officer · Jul 9, 2020 – Oct 12, 2020 · Past); Acer Therapeutics Inc (Chief Medical Officer · Oct 2, 2017 – Mar 2, 2020 · Past); Aegerion Pharmaceuticals Inc (See Remarks · Mar 29, 2015 – Aug 4, 2015 · Past) | Chief Medical Officer · Since at least Jun 2, 2025 |
| David S Tierney Other companies: Timber Pharmaceuticals Inc (Pres and CEO · Sep 11, 2018 – Jun 12, 2019 · Past); Zevra Therapeutics, Inc. (Director · Apr 15, 2015 – Mar 9, 2023 · Past); Bioject Medical Technologies Inc (Director · Jun 14, 2007 – Apr 30, 2014 · Past) | Director · Since at least Oct 27, 2015 |
| Daniel J. Curran Other companies: ALX Oncology Holdings Inc. (Director · Since at least Aug 12, 2025); Xilio Therapeutics, Inc. (Board Member · Since at least Oct 21, 2021) | Director · Since at least Aug 1, 2025 |
| Michael Wayne Kalb Other companies: CinCor Pharma Inc (EVP & Chief Financial Officer · Nov 4, 2022 – Feb 24, 2023 · Past); Amarin Corporation plc (SVP and CFO · Jun 30, 2016 – Jul 29, 2022 · Past) | Chief Financial Officer · Since at least Jan 1, 2024 |
| Philip H Coelho Other companies: Mediware Information Systems Inc (Director · Jan 3, 2012 – Nov 9, 2012 · Past); Ampio Pharmaceuticals, Inc. (Director · Nov 22, 2011 – Dec 30, 2021 · Past) | Director · Aug 25, 2015 – May 4, 2023 · Past |
| Richard J Daly Other companies: Aquestive Therapeutics, Inc. (Director · Since at least Nov 10, 2026); Opiant Pharmaceuticals Inc (Director · Jun 15, 2021 – Mar 2, 2023 · Past) | President and CEO, Director · Since at least Dec 22, 2020 |
| Tamar Thompson Other companies: Avidity Biosciences, Inc (Director · Since at least Jan 11, 2021) | Director · Since at least May 25, 2023 |
| Alicia Grande | VP, Treasurer and CFO · Aug 25, 2015 – Dec 27, 2023 · Past |
| Brian Elsbernd | Chief Legal Officer · Since at least Dec 27, 2018 |
| Chantal Dresner | VP of Marketing · Since at least Nov 4, 2025 |
All 24 people
| Person | Seat |
|---|---|
| Charles B O'Keeffe | Director · Aug 25, 2015 – Feb 14, 2025 · Past |
| Daniel Brennan | Chief Commercial Officer · Dec 2, 2019 – Dec 2, 2019 · Past |
| Donald A Denkhaus | Director · Since at least Dec 30, 2015 |
| Gary Ingenito | Chief Med. & Reg. Officer · Jun 30, 2015 – May 13, 2025 · Past |
| Gregg Russo | Chief HR Officer · Since at least Feb 13, 2025 |
| Internal Communication | Director · Since at least May 7, 2026 |
| Jeffrey Del Carmen | Chief Commercial Officer · Since at least Jun 23, 2020 |
| Mary Coleman | Investor Relations · Since at least Jan 23, 2025 |
| Molly Harper | Director · Since at least Jun 29, 2021 |
| Patrick J McEnany | Director · Since at least Aug 18, 2022 |
| Paul J Merrigan | Chief Commercial Officer · Sep 8, 2015 – Dec 30, 2015 · Past |
| Preethi Sundaram | Chief Strategy Officer · Since at least Jul 6, 2021 |
| Roberto Scrivo | Chief External Affairs Communication & Sustainability Officer · Since at least May 7, 2026 |
| Steve Miller | Chief Op. & Scientific Officer · Since at least Aug 25, 2015 |
Log in to ask 6ix AI your own questions about Catalyst Pharmaceuticals, Inc.